JP2024543138A5 - - Google Patents

Info

Publication number
JP2024543138A5
JP2024543138A5 JP2024531107A JP2024531107A JP2024543138A5 JP 2024543138 A5 JP2024543138 A5 JP 2024543138A5 JP 2024531107 A JP2024531107 A JP 2024531107A JP 2024531107 A JP2024531107 A JP 2024531107A JP 2024543138 A5 JP2024543138 A5 JP 2024543138A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
expression level
hdac6 inhibitor
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/082762 external-priority patent/WO2023094365A1/en
Publication of JP2024543138A publication Critical patent/JP2024543138A/ja
Publication of JP2024543138A5 publication Critical patent/JP2024543138A5/ja
Pending legal-status Critical Current

Links

JP2024531107A 2021-11-23 2022-11-22 Ｒｎａバイオマーカーの検出方法 Pending JP2024543138A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT202100029558 2021-11-23
IT102021000029558 2021-11-23
PCT/EP2022/082762 WO2023094365A1 (en) 2021-11-23 2022-11-22 Method to detect rna biomarkers

Publications (2)

Publication Number Publication Date
JP2024543138A JP2024543138A (ja) 2024-11-19
JP2024543138A5 true JP2024543138A5 (enExample) 2025-10-08

Family

ID=80121649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531107A Pending JP2024543138A (ja) 2021-11-23 2022-11-22 Ｒｎａバイオマーカーの検出方法

Country Status (9)

Country Link
US (1) US20250011878A1 (enExample)
EP (1) EP4437138A1 (enExample)
JP (1) JP2024543138A (enExample)
KR (1) KR20240105468A (enExample)
CN (1) CN118202068A (enExample)
AR (1) AR127708A1 (enExample)
CA (1) CA3235259A1 (enExample)
TW (1) TW202340480A (enExample)
WO (1) WO2023094365A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080842A1 (en) * 2023-10-11 2025-04-17 Dana-Farber Cancer Institute, Inc. Methods of cancer detection, prediction of response to therapy, and treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018499A2 (en) * 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
US20120176076A1 (en) 2011-01-10 2012-07-12 Carl Mansfield Methods and systems for powering auxiliary devices in photovol taic system
WO2014032899A1 (en) * 2012-08-31 2014-03-06 Novo Nordisk A/S Diagnosis and treatment of lupus nephritis
EP3084446B1 (en) * 2013-12-20 2022-12-14 Acetylon Pharmaceuticals, Inc. Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
CA2995520A1 (en) * 2015-08-14 2017-02-23 Hendrik Jan VAN OOIJEN Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
WO2017070441A1 (en) * 2015-10-23 2017-04-27 Icahn School Of Medicine At Mount Sinai Identifying and treating cancer patients who are suitable for a targeted therapy using an hdac6 inhibitor
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6

Similar Documents

Publication Publication Date Title
Hacker et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial
JP7065610B2 (ja) 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
Zare et al. Human endogenous retrovirus env genes: Potential blood biomarkers in lung cancer
JP2018502553A (ja) 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
Davidson et al. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
JP2016105731A5 (enExample)
JP2018078911A5 (enExample)
Xu et al. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer
CN103608683A (zh) Hedgehog抑制剂治疗的生物标志物
Hamid et al. Molecular regulatory roles of long non-coding RNA HOTTIP: an overview in gastrointestinal cancers
Cregan et al. KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma
WO2016174130A1 (en) Clinical gene signature-based human cell culture model and uses thereof
Liao et al. MiR-122 marks the differences between subcutaneous and visceral adipose tissues and associates with the outcome of bariatric surgery
US20180230545A1 (en) Method for the prediction of progression of bladder cancer
Stellato et al. Bone metastases from urothelial carcinoma. The dark side of the moon
JP6612232B2 (ja) 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
JP2017536085A5 (enExample)
Zhang et al. MiR-520d-5p functions as a tumor-suppressor gene in cervical cancer through targeting PTK2
Haapasalo et al. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas
JP2024543138A5 (enExample)
Tosi et al. Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
Yao et al. Role of the S100 protein family in liver disease
Zheng et al. Expression and clinical implications of homeobox gene Six1 in cervical cancer cell lines and cervical epithelial tissues
Wang et al. CircZFR promotes pancreatic cancer progression through a novel circRNA-miRNA-mRNA pathway and stabilizing epithelial-mesenchymal transition protein
Zhang et al. Higher RABEX-5 mRNA predicts unfavourable survival in patients with colorectal cancer.